Evidence map›Paper›PMID 34332377›Full record

ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021

A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.

Apu Chowdhury, Muhammad Sajid, Nabila Jahan, Temitope Isaac Adelusi, Pulak Maitra, Guolian Yin, Xudong Wu, Yuan Gao, Sicen Wang

Abstract readReview
In one paragraph

Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Apu ChowdhuryFaculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.
Muhammad SajidFaculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.
Nabila JahanSchool of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Temitope Isaac AdelusiComputational Biology/Drug Discovery Laboratory, Department of Biochemistry, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Pulak MaitraFaculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.
Guolian YinFaculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.
Xudong WuFaculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.
Yuan GaoFaculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.
Sicen WangSchool of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. Electronic address: wangsc@mail.xjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel coronavirus 2019 (COVID-19) is a zoonosis that revised the global economic and societal progress since early 2020. The SARS-CoV-2 has been recognized as the responsible pathogen for COVID-19 with high infection and mortality rate potential. It has spread in 192 countries and infected about 1.5% of the world population, and still, a proper therapeutic approach is not unveiled. COVID-19 indication starts with fever to shortness of breathing, leading to ICU admission with the ventilation support in severe conditions. Besides the symptomatic mainstay clinical therapeutic approach, only Remdesivir has been approved by the FDA. Several pharmaceutical companies claimed different vaccines with exceptionally high efficacy (90-95%) against COVID-19; how long these vaccines can protect and long-term safety with the new variants are unpredictable. After the worldwide spread of the COVID-19 pandemic, numerous clinical trials with different phases are being performed to find the most appropriate solution to this condition. Some of these trials with old FDA-approved drugs showed promising results. In this review, we have precisely compiled the efforts to curb the disease and discussed the clinical findings of Ivermectin, Doxycycline, Vitamin-D, Vitamin-C, Zinc, and cannabidiol and their combinations. Additionally, the correlation of these molecules on the prophylactic and diseased ministration against COVID-19 has been explored.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsAscorbic AcidCannabidiolCOVID-19Dietary SupplementsDoxycyclineDrug RepositioningDrug Therapy, CombinationHumansIvermectinTreatment OutcomeVitamin DZincAntiviral AgentsAscorbic AcidCannabidiolDoxycyclineIvermectinVitamin DZincCOVID-19DoxycyclineIvermectinVitamin-CVitamin-DZinc

Identifiers

PMID34332377
PMCPMC8313489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.